Mer­ck­'s Keytru­da wins an­oth­er first — this time for an FDA nod to treat a sub­set of blad­der can­cer pa­tients

Keytru­da, the star im­muno-on­col­o­gy ther­a­py des­tined to be­come the world’s best­selling drug by 2024, has se­cured ap­proval for a sub­set of blad­der can­cer pa­tients that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER